Product Description
AZD-5462 is being developed by AstraZeneca for cardiovascular disease indications. (Sourced from: https://clinicaltrials.gov/ct2/results?cond=&term=AZD-5462&cntry=&state=&city=&dist=)
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Czech Republic, Denmark, Hungary, India, Japan, Netherlands, Poland, Slovakia, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Failure, Chronic
Phase 1: Heart Failure|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06989983 |
D9090C00009 | P1 |
Completed |
Heart Failure |
2025-06-25 |
2025-07-08 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06661733 |
GLITTER | P1 |
Recruiting |
Kidney Diseases |
2025-04-28 |
2025-03-27 |
Primary Endpoints |
|
NCT06299826 |
LUMINARA | P2 |
Completed |
Heart Failure, Chronic |
2026-02-10 |
2026-02-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2023-510148-19-00 |
D9090C00008 | P2 |
Recruiting |
Heart Failure, Chronic |
2026-09-19 |
2025-05-02 |
Treatments |
|
jRCT2051240066 |
jRCT2051240066 | P2 |
Recruiting |
Heart Failure, Chronic |
2026-07-29 |
Recent News Events
Date |
Type |
Title |
|---|